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large preclinical animalmodel. In the results published in Plastic and Re-
constructive Surgery, they demonstrated the production of 80 ml of soft
tissue by encasing an AV loop (alone, with a muscle ﬂap, or with a fat
ﬂap) and a biodegradable sponge-like scaffold in a hard plastic chamber,
and implanting it subcutaneously in a pigmodel (Findlay et al., 2011). In
a reply in the same journal, Yuan suggests that the success of this ap-Tissue engineering and regenerativemedicine emerged at the end of
the 20th century and early 21st century, aiming to augment the healing
processes of the body to repair and/or regenerate injured ormissing tis-
sue. The idea of using a tissue engineering approach for breast regener-
ation is not a new one— Langer, Vacanti and Atala some of the pioneers
of tissue engineeringﬁrstﬁled a patent for such an idea in 1994 (Vacanti
et al., 1998) yet never pursued such a project reviewing the current lit-
erature (Vacanti et al., 1998; Chhaya et al., 2015a; Chhaya et al., 2015b).
There have been only a small number of teams truly investigating breast
tissue engineering (Chhaya et al., 2015a), with many more teams
(Giatsidis et al., 2015; Choi et al., 2010) researching scaffold and/or hy-
drogel based adipose tissue engineering more generally. Despite this,
surprisingly little progress has been made towards viable clinical appli-
cation, with as of yet only one human case study and only a few teams
producing clinically relevant volumes of tissue. A key problem limiting
tissue engineering is the regeneration of a vascular supply into a large
volume 3D construct, which is necessary to supply nutrients for tissue
growth (Chhaya et al., 2015a). This is especially important in adipose
tissue engineering, with fat cells being highly metabolically active and
undergoing necrosis when not adequately supplied with nutrients
(Kakagia and Pallua, 2014). Morrison's group has pioneered an alterna-
tive approach to vascularization by using an arterio-venous loop in
combination with a closed chamber, which had a hard casing design
(Morrison et al., 2016). After several landmark studies in small animals
which demonstrated the proof of concept, the group needed to modify
the chamber design as several studies showed limited tissue formation
in the chamber especially in the process of upscaling the volume. This
was may be due to secondary shrinkage of the initial blood clot in the
chamber, or entrapment of air in the closed chamber preventing the re-
quired blood clot and/or vascularized ﬂap micro-movements.om.2016.03.032.
pen access article under the CC BY-NMorrison's group then changed the concept and used a porous
chamber and/or a scaffold. This concept was ultimately studied in a
proach was due to the modulation of physical forces promoting adipo-
genesis (Yuan and Ogawa, 2015). In other work Yuan has shown that
adipogenesis is inhibited by mechanical forces in contrast to musculo-
skeletal tissues that are known to proliferate in response to physical
stress — this is consistent with the observation of volume loss in
lipoﬁlling (Yuan and Ogawa, 2015). And the encouraging results have
been used by the group to generate a clinically relevant volume of adi-
pose tissue, which they herald as paving the way to human trials pre-
sented in this issue of EBioMedicine (Morrison et al., 2016). Although
we aim for regeneration as an ultimate result, this is very hard to
accomplish.
While the work of Morrison et al. (2016) in EBioMedicine is signiﬁ-
cant as the ﬁrst group to engineer clinically relevant volumes of adipose
tissue in humans, its widespread clinical application of the current tech-
nique is questionable. This approach requires the implantation of what
could be deﬁned as a hard casing that may not be comfortable for the
patient, as well as an additional operation for removal. The mixed clin-
ical results may be related to that the authors changed their original
chamber concept, whichwas studied in the pigmodel to a dome shaped
porous sheet, whichwas completely open towards the chest wall of the
patient. Furthermore, the authors did decide against using a scaffold
even so the pig results were better in the scaffold group. One might
get the impression that the authors are admitted contrarians to the cur-
rent knowledge in scaffold design and fabrication. Awell-designed fully
interconnected large pore network allows the formation of a blood clot
inside the scaffold architecture (Holzapfel et al., 2013). The clot consists
of platelets embedded in a mesh of cross-linked ﬁbrin ﬁbers, together
with a growth-factor rich cocktail of ﬁbronectin, ﬁbronectin and
thrombospondin. It is well known in the literature that the ﬁbrin net-
work and the associated growth-factor cocktail stimulates a strong an-
giogenic response and induce highly organized connective tissue to
penetrate into the affected region. As seen by the others in previous an-
imal studies and well known by another concept called guided bone re-
generation (GBR) in which space maintain concept has been used
clinicallywith high success for decades (Nyman, 1991). GBR uses biode-
gradable or originally non-resorbablemembrane that acts as a barrier to
prevent soft-tissue invasion into the defect and forms a chamber toC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1990) it was shown that in large bone defects, bone formation occurs
only to the marginal stable zone with a central zone of disorganized
loose connective tissue, and, therefore, additional use of bone-graft ma-
terials is required in these cases, with the bone graft acting as a scaffold
for the formation of blood clot in combination with a stable ﬁbrin net-
work which is a condition sine qua non to allow mesenchymal precur-
sor cells to migrate into the defect and develop the microenvironment
for osteoinductive extracellular matrix which ultimately lead to large
volume bone formation (Nyman, 1991). The regeneration of any large
volume mesenchymal tissue is based on certain biological principles,
which should be taken into account for any tissue engineering strategy,
which aims at clinical translation (Yannas, 2013).
In the past decades, a series of transformations have changed the
way in which researchers decipher diseases and develop new treat-
ments. Among other signiﬁcant shifts in biomedical research, scientists,
educators as well as funding agencies are moremindful of the necessity
of aligning highly qualiﬁed interdisciplinary teams, encouraging people
with very different expertise and technical skills, such as biologists, en-
gineers, chemists, physicists, mathematicians, medical doctors and vet-
erinary surgeons, to work together towards advancing our knowledge
in medicine. This becomes particularly important when aiming to de-
velop patient-speciﬁc platforms for personalized medicine. As seen in
the current study, the challenges that arisewhenworking in such inter-
disciplinary teams are not trivial, and among other tasks a lot of work
still needs to be done in order to bridge more effectively the existing
gap created by the different technical terminologies andmethodologies
speciﬁc to each discipline.
The future of tissue engineering and speciﬁcally the clinical compan-
ion regenerative medicine relies upon the investment in continuing to
make it the pinnacle of biomedical research. Rapid advances of transla-
tional research into the development of tissue engineering technology
platforms have the potential to start a new era in personalized medi-
cine. Regenerative medicine will thus grow in conjunction with the re-
alization of individualized medicine paradigms to create predictive,
personalized, and preemptive solutions for tailored delivery of
patient-speciﬁc health care. In closing, the authors concluded rightlythat the ﬁrst steps are completed yet ongoing research is required
aiming to establish an ideal chamber concept for breast/adipose tissue
regeneration with optimized characteristics in terms of biocompatibil-
ity, space-making, tissue integration and clinicalmanageability formax-
imum clinical efﬁcacy and safety.Disclosure
The author declares to have an active research programonbreast tis-
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